1-methyl-3-(o-tolyl)urea | 13278-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-methyl-3-(o-tolyl)urea
• 英文别名: 3-methyl-1-(4-tolyl)urea；N-methyl-N'-(2-methylphenyl)urea；1-methyl-3-(2-methylphenyl)urea
• CAS: 13278-63-2
• 化学式: C₉H₁₂N₂O
• mdl: MFCD00025630
• 分子量: 164.207
• InChiKey: YEHMKQZZSLVLEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methyl-3-(o-tolyl)urea 在 palladium on activated charcoal 盐酸 、 sodium hydroxide 、 氢气 、 乙酸酐 、 sodium nitrite 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 13.0h， 生成 5,6-二氨基-3-甲基-1-(2-甲基苯基)嘧啶-2,4-二酮
  参考文献：
  名称：

  Structure and activity relationships of novel uracil derivatives as topical anti-inflammatory agents

  摘要：

  In order to create novel, topical anti-inflammatory compounds exhibiting more potent activities than lead compound CX-659S (1), we designed and synthesized various derivatives of 1 focusing on the uracil N(l)- and N(3)-substituents, and evaluated their anti-inflammatory activities via inhibition of the picryl chloride-induced contact hypersensitivity reaction (CHR) in mice. In the course of our structure and activity relationship study, we found that compounds 6k, 6q, and 6r inhibited by approximately 50% the CHR, at 0.1 mg/ear. These activities were essentially equipotent with that of Tacrolimus, a strong immunosuppressant. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.09.012
• 作为产物：
  描述：

  2-乙炔基甲苯 在 三苯基膦氯金 、 氟化银 、 叠氮基三甲基硅烷 、 水 、 三氟甲磺酸 作用下， 以 三氯乙烯 为溶剂， 反应 4.08h， 以51%的产率得到1-methyl-3-(o-tolyl)urea
  参考文献：
  名称：

  将基质分为三个部分：C对金进行炔烃的氮催化硝化作用？C和CC键断裂

  摘要：

  炔烃为carbamides的合成和至C氨基四唑的金催化的氮化 C和CC键断裂进行说明。在温和条件下选择性地构建了多种功能化的脲和氨基四唑衍生物。通过选择酸添加剂可以容易地切换化学选择性。该反应的特点是底物范围广，可直接构建高价值的产品，易于在空气中操作以及在室温下温和的条件。通过将底物分为三部分，该化学方法提供了一种转化炔烃的方法。

  DOI：

  10.1002/anie.201508347

文献信息

• SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US20180179151A1

  公开（公告）日：2018-06-28

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，表现出促进俄利班受体活性，并且预计可用作嗜睡症等疾病的预防或治疗药物。本发明提供一种由式(I)表示的化合物：其中每个符号如描述中定义，或其药用可接受的酸盐，具有促进俄利班受体活性，并且含有该化合物或其药用可接受的酸盐的俄利班受体激动剂。
• Endothelin antagonistic substance
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0555537A2

  公开（公告）日：1993-08-18

  A peptide derivative of the formula: wherein A is a group of the formula R"O-CO- (wherein R11 is a lower alkyl group or a phenyl group), or a group of the formula R12R13N-C(=O)- (wherein R12 is a lower alkyl group, a cycloalkyl group, a 1-adamantyl group, a phenyl group wherein one or two optional hydrogen atoms on the benzene ring may independently be replaced by a halogen atom, a trifluoromethyl group, a nitro group, an amino group or a formylamino group, a pyridyl group, or a thienyl group, R13 is a hydrogen atom, a lower alkyl group or a cycloalkyl group, or R12 and R13 form, together with the adjacent nitrogen atom, a 5- to 9-membered nitrogen-containing saturated heterocyclic ring having 4 to 8 carbon atoms, wherein among methylene groups forming the ring, one optional methylene group not adjacent to the above nitrogen atom may be replaced by a thio group, and one to four optional hydrogen atoms on the carbon atoms of the heterocyclic ring may independently be replaced by a lower alkyl group, and further two adjacent carbon atoms in the heterocyclic ring may form a benzo-fused ring); B is an oxygen atom or a group of the formula -NR2- (wherein R2 is a hydrogen atom or a lower alkyl group); R3 is a lower alkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, a cycloalkyl lower alkyl group, an aryl lower alkyl group or a heterocyclic lower alkyl group; X1 is an oxygen atom or a group of the formula -NR4- (wherein R4 is a hydrogen atom or a lower alkyl group); R5 is a 3-indolylmethyl, 3-benzothienylmethyl, 1-naphthylmethyl or benzyl group wherein one or two optional hydrogen atoms on the ring may be replaced by a hydroxyl group, a halogen atom, a formyl group, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkoxycarbonyl group, a nitro group or a group of the formula R51-CO-X-2 wherein R51 is a lower alkyl group, a lower alkoxy group, or an amino group which may be substituted by a lower alkyl group, and X2 is an oxygen atom or a group of the formula -NR52- (wherein R52 is a hydrogen atom or a lower alkyl group)}; X3 is an oxygen atom or a sulfur atom; R6 is a hydrogen atom, or a lower alkyl or lower alkenyl group which may have a substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a lower alkylthio group and a heterocyclic group; n is 0 or 1; Y is a hydroxymethyl group, a group of the formula CO2R71 (wherein R71 is a hydrogen atom or a lower alkyl group), a group of the formula CONHR72 (wherein R72 is a hydrogen atom or a lower alkyl group which may have a substituent selected from the group consisting of a hydroxyl group, a carboxyl group and a sulfo group), a 1 H-tetrazol-5-yl group, a sulfo group and a phosphono group; or a pharmaceutically acceptable salt thereof.

  式中的肽衍生物： 其中 A 是式 R "O-CO- 的基团（其中 R11 是低级烷基或苯基），或式 R12R13N-C(=O)- 的基团（其中 R12 是低级烷基、环烷基、1-金刚烷基、苯基，其中苯环上的一个或两个任选氢原子可独立地被卤素原子、三氟甲基、硝基、氨基或甲酰氨基、吡啶基或噻吩基取代，R13 是氢原子、低级烷基或环烷基、或 R12 和 R13 与相邻的氮原子一起形成具有 4 至 8 个碳原子的 5 至 9 元含氮饱和杂环，其中在形成环的亚甲基中，不与上述氮原子相邻的一个任选亚甲基可被硫代基团取代，杂环碳原子上的 1 至 4 个任选氢原子可独立地被低级烷基取代，杂环中的另外两个相邻碳原子可形成苯并融合环），R12 和 R13 与相邻的氮原子一起形成具有 4 至 8 个碳原子的 5 至 9 元含氮饱和杂环，其中在形成环的亚甲基中，不与上述氮原子相邻的一个任选亚甲基可被硫代基团取代，杂环碳原子上的 1 至 4 个任选氢原子可独立地被低级烷基取代，杂环中的另外两个相邻碳原子可形成苯并融合环）；B 是氧原子或式-NR2-的基团（其中 R2 是氢原子或低级烷基）； R3 是低级烷基、环烷基、芳基、杂环基、环烷基低级烷基、芳基低级烷基或杂环低级烷基； X1 是氧原子或式-NR4-的基团（其中 R4 是氢原子或低级烷基）；R5是3-吲哚甲基、3-苯并噻吩甲基、1-萘甲基或苄基，其中环上的一个或两个任选氢原子可被羟基、卤素原子、甲酰基、低级烷基、低级烷氧基、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基取代、低级烷氧基羰基、硝基或式 R51-CO-X-2 的基团其中 R51 为低级烷基、低级烷氧基或可被低级烷基取代的氨基，X2 为氧原子或式 -NR52- 的基团（其中 R52 为氢原子或低级烷基）}；X3 是氧原子或硫原子；R6 是氢原子，或低级烷基或低级烯基，其取代基可选自由羟基、低级烷氧基、低级烷硫基和杂环基组成的组；n 是 0 或 1；Y 是羟甲基、式 CO2R71 的基团（其中 R71 是氢原子或低级烷基）、式 CONHR72 的基团（其中 R72 是氢原子或低级烷基，其取代基可选自由羟基、羧基和磺基组成的组）、1H-四唑-5-基、磺基和膦基；或其药学上可接受的盐。
• Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
  申请人：UNIVERSITY OF TSUKUBA

  公开号：US10351522B2

  公开（公告）日：2019-07-16

  The present invention aims to provide a novel low-molecular-weight compound exhibiting an orexin receptor agonist activity and expected to be useful as a prophylactic or therapeutic agent for narcolepsy and the like. The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable acid addition salt thereof, which has an orexin receptor agonist activity, and an orexin receptor agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

  本发明旨在提供一种新型低分子量化合物，该化合物具有奥曲肽受体激动剂活性，有望用作嗜睡症等的预防或治疗药物。本发明提供了一种由式（I）代表的化合物： 其中各符号如描述中所定义，或其药学上可接受的酸加成盐，具有奥曲肽受体激动剂活性，以及含有该化合物或其药学上可接受的酸加成盐的奥曲肽受体激动剂。
• Tanno, Masayuki; Sueyoshi, Shoko, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 4, p. 1360 - 1371
  作者：Tanno, Masayuki、Sueyoshi, Shoko

  DOI：——

  日期：——
• TANNO MASAYUKI; SUEYOSHI SHOKO, CHEM. AND PHARM. BULL., 35,(1987) N 4, 1360-1371
  作者：TANNO MASAYUKI、 SUEYOSHI SHOKO

  DOI：——

  日期：——